Aptinyx: Jumps on restarting trial of dementia treatment

Aptinyx

06/04/2021 12:15

** Shares of drug developer  APTX.O  surge 8.3% to $3.49
premarket
    ** Co says http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210406:nBw27nSRVa&default-theme=true
 it has recommenced mid-stage trial of its experimental drug,
NYX-458, in patients with cognitive impairment associated with
Parkinson's disease and Dementia with Lewy bodies 
    ** Study had been suspended due to escalation of COVID-19
pandemic
    ** Trial to enroll approximately 100 patients
    ** Aptinyx anticipates reporting data from study in H2 2022
    ** Approx 1.4 mln people in U.S. suffer from cognitive
impairment due to Parkinson's disease or Dementia with Lewy
Bodies - APTX

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))